Objective: To evaluate the efficacy and safety of low-dose prourokinase (pro-UK) administration during primary percutaneous coronary intervention (PCI) for the treatment of acute ST-segment elevation myocardial infarction (STEMI) in patients with a high thrombus burden.

Methods: A prospective, randomized controlled trial was conducted at the Inner Mongolia People's Hospital, China. Patients with STEMI and a high thrombus burden who underwent thrombus aspiration and primary PCI were randomly allocated to pro-UK administration or control groups. The primary endpoint was corrected thrombolysis in myocardial infarction (TIMI) frame count (CTFC).

Results: There were no significant differences in the baseline demographics or clinical characteristics of the two groups. The CTFC, tissue myocardial perfusion grade, ST-segment resolution, and myocardial blush grade of the pro-UK group were significantly better than those of the control group. In addition, after 30 days of follow-up, the pro-UK group had better cardiac function and perfusion than the control group. There were no differences in the clinical outcomes or incidence of hemorrhage.

Conclusions: Intracoronary low-dose pro-UK improves myocardial perfusion and cardiac function in patients with a high thrombus burden. Major hemorrhages still occur in patients administered pro-UK, but are no more frequent.: Chinese Clinical Trial Registry (ChiCTR1900022290).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756369PMC
http://dx.doi.org/10.1177/03000605221139723DOI Listing

Publication Analysis

Top Keywords

high thrombus
16
myocardial infarction
12
thrombus burden
12
intracoronary low-dose
8
low-dose prourokinase
8
st-segment elevation
8
randomized controlled
8
controlled trial
8
pro-uk administration
8
patients high
8

Similar Publications

Snakebites are critical medical emergencies that significantly contribute to emergency department visits during monsoon seasons. This case report details a patient who experienced simultaneous arterial and venous thrombosis of major intracranial vessels due to venom-induced consumptive coagulopathy. Additionally, the patient developed diffuse alveolar haemorrhage (DAH), highlighting the severe impact of these uncommon complications on prognosis.

View Article and Find Full Text PDF

Improving the management of polycythemia vera patients eligible for cytoreduction: report of a multidisciplinary advisory board.

Curr Med Res Opin

January 2025

Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.

Introduction: The management of patients with Polycythemia Vera (PV) traditionally includes low-dose aspirin, phlebotomy, and cytoreductive therapy for high-risk individuals. Recent evidence suggests that cytoreductive treatment may be warranted for patients with additional risk factors beyond the traditional criteria of a history of thrombosis and age over 60 years. Introducing new therapeutic agents, including ropeginterferon alfa-2b and ruxolitinib, enables a more personalized treatment approach tailored to individual patient characteristics.

View Article and Find Full Text PDF

Background: Acute aortic dissection is a life-threatening cardiovascular emergency with high mortality rates. Disseminated intravascular coagulation (DIC) is a critical complication in patients with acute aortic dissection; however, its incidence and impact on outcomes remain inconclusive.

Objectives: This study aimed to evaluate DIC prevalence and prognosis in patients with aortic dissection.

View Article and Find Full Text PDF

Thoracoabdominal aortic aneurysm (TAAA) repair remains one of the most challenging procedures and is associated with high mortality and complication rates. Careful consideration of the surgical strategy is essential, particularly in cases involving extensive replacement and high-risk patients. A 61-year-old man with a 55-mm TAAA was referred for surgical treatment.

View Article and Find Full Text PDF

Background: The effectiveness and preferred reconstruction methods of pancreatectomy associated with vein resection (PAVR) for pancreatic cancer, especially for the extensive portal vein/superior mesenteric vein (PV/SMV) resections (more than 4 cm), are still subjects of debate. The aim of this study is to evaluate the safety and feasibility of PAVR by analyzing data from two large institutions from different regions.

Methods: From 2008 to 2018, we identified consecutive series of patients with pancreatic cancer who underwent PAVR at Karolinska University Hospital (KUH), Sweden, and Cancer Institute Hospital, Japanese Foundation of Cancer Research (JFCR), Japan.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!